Federal contractor · AMES, IA

NEOVAXSYN INC

No contract obligations recorded for NEOVAXSYN INC in FY2026. Since FY2020: $3.2M. Its largest customer was National Institutes of Health ($0). It also received $300K in federal grants and other assistance in FY2026.

Obligations · FY2026
$0
New awards
1
Sole-source
—
Single offer
—
UEI
EHMTBALCKFE8
Small businessMinority-owned
Open in the contracts explorerRelationship graph

Spending by fiscal year

Obligations per federal fiscal year (October–September).

  1. 300KFY2020
  2. 300KFY2021
  3. 300KFY2022
  4. 0FY2023
  5. 2.3MFY2024
  6. 0FY2025
  7. 0FY2026

Top buying agencies

Obligations in FY2026.

  1. National Institutes of Health$00.0%
    1 awards

What was bought · Where the work was performed

Obligations in FY2026.

What was bought

Where the work was performed

Integrity signals

Shares of the year's obligations, next to the country's.

Largest awards

  1. NANOVACCINE FOR ELICITING BNABS AGAINST HIV-1$2M
    National Institutes of Health· Story County, IA· Research & development· Jun 25, 2024 – Jun 25, 2026· 75N93024C00019

Federal grants & assistance received

Grants, loans (counted at their subsidy cost), direct payments and insurance, by fiscal year of the action (USAspending.gov, FABS). Reported apart from contracts and never added to them.

NEOVAXSYN INC received $300K in federal assistance in FY2026, on 1 actions (1 new awards). Its largest program was 93.855 · Allergy and Infectious Diseases Research ($300K).

Assistance · FY2026
$300K
New awards
1
Actions
1
Since FY2021
$966.9K

Assistance by fiscal year

  1. 69.6KFY2021
  2. 297.3KFY2022
  3. 300KFY2023
  4. 0FY2024
  5. 0FY2025
  6. 300KFY2026

By type

  1. Grants$300K100%

Top programs

  1. 93.855 · Allergy and Infectious Diseases Research$300K100%

Awarding agencies

  1. National Institutes of Health$300K100%
    Department of Health and Human Services

Largest awards

  1. A NOVEL STRATEGY FOR THE NEXT GENERATION RAAV GENE THERAPY AND VACCINE VECTOR PRODUCTION - PROJECT SUMMARY/ABSTRACT DESPITE THE COMMERCIAL…$300K
    93.855 · Allergy and Infectious Diseases Research· National Institutes of Health· Project grant· Aug 27, 2026 – Aug 27, 2026· R43AI197694

Source: Federal financial assistance transactions (Financial Assistance Broker Submission) (U.S. Department of the Treasury, USAspending.gov), data current to Oct 8, 2026, loaded Oct 8, 2026 · FY2021–FY2026.

Competitors

Companies that win from the same buyers in the same markets: obligations by agency and industry compared over the last three fiscal years.

Compared on 1 market (agency × industry), FY2024–FY2026.

  1. PHARMACOLOGY DISCOVERY SERVICES TAIWAN, LTD.$2.2M+458% in FY2026
    NEW TAIPEI CITY, TWN · 97% of this company's obligations are in markets they both serveNational Institutes of Health · Scientific research and development services
  2. DOSEOPTICS LLC$2.4M−100% in FY2026
    LEBANON, NH · 100% of this company's obligations are in markets they both serveNational Institutes of Health · Scientific research and development services
  3. BIOSENSICS LLC$2.4M
    NEWTON, MA · 100% of this company's obligations are in markets they both serveNational Institutes of Health · Scientific research and development services

Showing the top 3 of 25 competitors. Open the profile for the full list.

Who sells to the same buyers in the same markets, not who wins against whom on a given contract. Prime contract obligations by the agency and NAICS code of each award; subawards are never added. A company is a family of legal entities, joined by parent UEI or, in part, by an AI reading of names.

Source: Federal contract transactions (Federal Procurement Data System) (U.S. Department of the Treasury, USAspending.gov), data current to Oct 9, 2026, loaded Oct 9, 2026 · FY2024–FY2026.

Source: Federal contract transactions (Federal Procurement Data System) (U.S. Department of the Treasury, USAspending.gov), data current to Oct 9, 2026, loaded Oct 9, 2026.